J.P. Morgan analyst Jessica Fye has maintained their bullish stance on ALNY stock, giving a Buy rating on June 26.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jessica Fye’s rating is based on the strong sales momentum observed for Alnylam Pharma’s Amvuttra, as indicated by the IQVIA data for May. The sales figures suggest a robust performance in the second quarter, with potential for significant growth compared to the first quarter. This growth is supported by a consistent increase in sales from March to May, indicating a promising trajectory for the company’s TTR franchise.
Furthermore, the analysis projects that even in a conservative scenario, there is considerable upside potential to the current sales estimates for the second quarter. This optimism is further bolstered by the possibility of an upward revision in the company’s 2025 TTR franchise guidance, as the first half of the year could achieve a substantial portion of the annual target. These factors collectively contribute to the Buy rating, reflecting confidence in Alnylam Pharma’s continued growth and market performance.
In another report released on June 26, Needham also maintained a Buy rating on the stock with a $377.00 price target.